Placebo (low dose)

DRUG3 trials

Sponsors

Boehringer Ingelheim

Conditions

Diabetes Mellitus, Type 2

Phase 2

4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)

CompletedNCT00885118

Boehringer IngelheimDiabetes Mellitus, Type 2

Start: 2009-04-30Updated: 2014-11-25

Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

CompletedNCT01193218

Boehringer IngelheimDiabetes Mellitus, Type 2

Start: 2010-09-30End: 2012-06-30Updated: 2014-06-17

Phase 3

Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus

CompletedNCT01368081

Boehringer IngelheimDiabetes Mellitus, Type 2

Start: 2011-05-31End: 2013-04-30Updated: 2014-06-17

Related Papers

Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes.

2018-02-2751 citations

Efficacy and safety of empagliflozin in Japanese patients with type 2 diabetes mellitus: A sub-analysis by body mass index and age of pooled data from three clinical trials

Diabetes Research and Clinical Practice2017-07-0817 citations

Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in <scp>J</scp>apanese patients with type 2 diabetes mellitus

Journal of Diabetes Investigation2013-06-2542 citations